Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BrainAurora Medical Technology Limited ( (HK:6681) ) has provided an update.
BrainAurora Medical Technology Limited, through its indirect wholly owned subsidiary Zhejiang BrainAurora Medical Technology, has entered into a year-long Cognitive Digital Therapeutics Cooperation Agreement with Beijing Jianguo Medical Technology to advance digital therapeutics for cognitive impairment in China’s mental health and social welfare systems. The collaboration aims to standardize and scale the application of cognitive function assessment and training, including joint research on national technical standards, a multi-center pilot rollout of the BrainAurora Cognitive Function Assessment and Training System across several Chinese cities, and the creation of a long-term, multi-regional research cohort whose jointly owned data will support future policy-making, technology upgrades, and iterative improvements to digital therapeutic standards.
The most recent analyst rating on (HK:6681) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on BrainAurora Medical Technology Limited stock, see the HK:6681 Stock Forecast page.
More about BrainAurora Medical Technology Limited
BrainAurora Medical Technology Limited is a medical technology company focused on developing and commercializing digital therapeutics and related systems for cognitive function assessment and training, with a particular emphasis on cognitive impairment and mental health applications in China.
Average Trading Volume: 16,161,135
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.61B
For an in-depth examination of 6681 stock, go to TipRanks’ Overview page.